EMA Recommends Extension of Therapeutic Indications for Retifanlimab By Ogkologos - February 6, 2026 385 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of adult patients with squamous cell carcinoma of the anal canal Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Osimertinib Shows Promising Activity in Previously Untreated Patients with Metastatic NSCLC... December 19, 2023 FDA Grants Accelerated Approval to Futibatinib for Cholangiocarcinoma October 6, 2022 What Are Drug Shortages and How Can They Impact Care for... June 23, 2023 Mom Of Three Fought Breast Cancer, Drought, And Australia Bushfires In... January 8, 2020 Load more HOT NEWS Tables Turned After a Breast Cancer Diagnosis, Men May Be More Likely to... Adolescent and Young Adult Cancer Survivors Face More Co-morbidity in Later... New on NCI’s Websites for June 2023
